Review Article

Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image

  • Views: 239

  • Likes: 0

  • Downloads: 49

  • Read time: 16m 48s
Average (ratings)
No ratings
Your rating

Abstract

Cardiac reverse remodelling (RR) is a complex process involving structural and functional recovery of the myocardium, with significant implications for the prognosis of patients with heart failure (HF). This review summarises current concepts, underlying mechanisms, therapeutic strategies, and clinical implications of RR, while distinguishing it from myocardial recovery and remission. Both pharmacological therapies and non-pharmacological interventions have shown potential to induce RR in selected populations. Clinical features, echocardiographic parameters, advanced imaging findings, and biomarkers help stratify patients according to the likelihood of recovery and risk of relapse. The management of HF with improved ejection fraction remains debated. High recurrence rates are seen after therapy discontinuation; however, evidence suggests that partial withdrawal may be safe in specific patient profiles. RR should be considered a central therapeutic goal in HF care, although its extent and stability vary widely. Differentiating between transient improvement, remission under therapy, and true myocardial recovery is critical for guiding long-term treatment decisions, highlighting the importance of individualised follow-up.

Keywords

Reverse remodelling, myocardial recovery, heart failure, improved ejection fraction, pharmacological therapy, prognosis.,

Received:

Accepted:

Published online:

DOI: https://doi.org/10.15420/cfr.2025.41

Disclosure: SRF has received travel support from Pfizer. MTSSL has received speaker honoraria from AstraZeneca. EAB has received consulting fees from Servier, AstraZeneca and Boehringer Ingelheim; subsidised travel/registration fees/hotel fees from Servier; membership in steering committees from Servier, Novartis and Boehringer Ingelheim; research grant support through Heart Institute from Jansen, Bayer/Merck, AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, Cardiol Therapeutics and Eurofarma; and honoraria form Servier, Novartis, Astra-Zeneca and Boehringer Ingelheim. SMAF has received honoraria from Abbott, Novartis and CSL Vifor. All other authors have no conflicts of interest to declare.

Correspondence: Silas Ramos Furquim, Heart Failure Department, Instituto do Coração, R. Dr Eneas de Carvalho Aguiar 44, São Paulo 05403-900, Brazil. E: silas.furquim@hc.fm.usp.br

Copyright:

© The Author(s). This work is open access and is licensed under CC-BY-NC 4.0. Users may copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Over the past three decades, heart failure (HF) management has advanced significantly, transforming the prognosis of a condition once regarded as inevitably progressive. This therapeutic evolution has led to substantial improvements in both quality of life and patient survival, often evidenced by structural recovery assessed via objective parameters such as left ventricular ejection fraction (LVEF); this structural recovery is known as reverse remodelling (RR).1

RR has become an increasingly recognised and desirable outcome in clinical practice. Patients with left ventricular (LV) RR have 5-year survival rates between 80% and 90%, compared with the 65–75% in those with persisting reduced LVEF.2–5 Moreover, RR is independently associated with lower rates of mortality, HF-related hospitalisations and heart transplantation, even after adjustment for baseline LVEF, duration of HF, functional class and β-blocker therapy.6–8

Recognising the clinical and prognostic relevance of this subgroup, recent guidelines have introduced the classification ‘HF with improved ejection fraction’ (HFimpEF) to describe individuals who, following an initial diagnosis of HF with reduced ejection fraction (HFrEF), demonstrate significant improvement in LVEF.9,10 However, the clinical management of the HFimpEF phenotype remains surrounded by uncertainty: some patients remain at risk of recurrent deterioration, while others appear to achieve sustained recovery.11

For this reason, the literature has proposed terms such as ‘myocardial remission’, to describe functional improvement that may be transient and dependent on continued therapy, and ‘myocardial recovery’ to denote cases in which functional normalisation is more complete and potentially independent of ongoing treatment, particularly when the primary causal factor has been eliminated.6,12,13 Scientific literature addressing the long-term evolution and optimal therapeutic strategies for these patients remains relatively scarce, although it is steadily expanding.

The aim of this review is to comprehensively present and discuss the concepts of RR, HFimpEF, myocardial recovery and myocardial remission. It will address the underlying pathophysiological mechanisms, clinical and prognostic implications, predictors of RR occurrence and sustainability, associated therapies, current knowledge gaps, and the current recommended clinical management approach.

Methods

We conducted a comprehensive narrative review of the literature on cardiac reverse remodelling in HFrEF. A systematic search was performed in the PubMed, Embase and Cochrane databases from January 2010 to July 2025, using the following search terms: ‘reverse remodelling’, ‘heart failure’, ‘improved ejection fraction’, ‘myocardial recovery’ and ‘remission’. We included original research articles, systematic reviews, meta-analyses, clinical trials and consensus statements published in English. Priority was given to recent publications (2020–2025), landmark studies, and guidelines from major cardiovascular societies. Additional references were identified through manual review of bibliographies from selected articles. We excluded case reports, editorials and studies focusing exclusively on paediatric populations. This review synthesises the current evidence on definitions, epidemiology, pathophysiology, therapeutic strategies and clinical management of RR, with an emphasis on practical clinical applications and recent therapeutic advances.

Definition and Classification

RR refers to the process by which a previously dilated and dysfunctional left ventricle undergoes normalisation, or substantial improvement, in its geometry and contractile function. This recovery may occur spontaneously in certain aetiologies, but more commonly results from effective therapeutic interventions, often leading to improvement in HF symptoms.14

Despite the growing clinical relevance of this phenomenon, major international guidelines have yet to reach consensus on its definition and classification criteria.15–17 An attempt at standardisation was proposed in 2021 through a consensus statement developed by the American, European and Japanese Heart Failure Societies.18 That document recommended the classification of HFimpEF for patients with documented baseline LVEF ≤40%, who subsequently demonstrate an absolute increase in LVEF of at least 10%, resulting in a follow-up LVEF >40%.19 Similarly, an expert panel from the Journal of the American College of Cardiology proposed a comparable definition: baseline LVEF <40%, an absolute increase of ≥10%, and a subsequent LVEF >40%. Furthermore, that document differentiated between complete LVEF normalisation, defined as LVEF >50%, and partial normalisation when LVEF is between 40% and 50%.6

In contrast, neither the 2022 American College of Cardiology/American Heart Association (ACC/AHA) guidelines nor the 2021 European Society of Cardiology (ESC) guidelines adopted these prior definitions. The ACC/AHA guidelines define improved LVEF simply as a baseline value ≤40% and a follow-up value >40%, whereas the ESC considers HFimpEF when baseline LVEF ≤40% subsequently improves to ≥50%.15 Neither guideline specifies a minimum time interval required before reassessing LVEF.15,16 Supplementary Table 1 summarises the main definitions proposed.

It is crucial to recognise that even after RR and apparent normalisation of ventricular structure, biomarkers and symptom resolution, a significant proportion of patients remain at risk for HF recurrence.11 This has led some authors to consider the condition as myocardial remission rather than a true cure.20,21 In contrast, the term ‘myocardial recovery’ would be more appropriate in scenarios in which complete removal of the primary stressor leads to restoration of cardiac function with low likelihood of HF recurrence.22

Epidemiology

The prevalence of RR in patients with HFrEF is influenced by multiple factors, including the specific definition used, population characteristics, and critically, the aetiology of ventricular dysfunction. General estimates indicate that RR can be observed in approximately 26–46% of HFrEF patients, reflecting the inherent heterogeneity of this phenomenon.13

In a cohort of patients with sustained RR (Figure 1), the distribution of aetiologies reflects the complexity and heterogeneity of HF populations in clinical practice, with important implications for prognosis and therapeutic decision-making.23

Figure 1: Reverse Remodelling Outcomes by Cardiomyopathy Aetiology

Article image
Download

Reversible Aetiologies

Conditions associated with acute and potentially transient insults demonstrate the greatest potential for functional recovery. In tachycardia-induced cardiomyopathy, takotsubo syndrome and thyrotoxicosis-related cardiomyopathy, complete improvement in LVEF may occur in 60–100% of cases after resolution of the triggering factor.9 Acute lymphocytic myocarditis and peripartum cardiomyopathy also have high rates of functional recovery. There is substantial evidence of RR following withdrawal of cardiotoxic agents.

Anthracycline-induced cardiomyopathy shows recovery potential in 30–50% of cases when detected early and cardiotoxic therapy is discontinued. Similar patterns are observed with tyrosine kinase inhibitors and monoclonal antibodies, emphasising the importance of early detection and intervention.24

Chronic Aetiologies

In contrast, chronic aetiologies with higher likelihood of irreversible myocardial injury tend to have lower degrees of RR. Ischaemic cardiomyopathy consistently shows the lowest rates of functional recovery, with RR occurring in approximately 15–25% of patients. Studies evaluating response to cardiac resynchronisation therapy (CRT) have demonstrated that patients with non-ischaemic cardiomyopathy experience greater mean improvements in LVEF than those with ischaemic aetiology.

Idiopathic dilated cardiomyopathy presents more favourable outcomes, with average increases in LVEF of up to 22.4% and significant reductions in major cardiovascular events.25 This difference is likely to reflect the absence of irreversible ischaemic injury and the potential for more complete myocardial recovery.

Surgical Interventions

Following surgical correction of aortic valvular disease, regression of hypertrophy and functional normalisation occurs in more than half of patients. Importantly, postoperative echocardiographic parameters are more predictive of LVEF improvement than preoperative values, suggesting that the degree of irreversible myocardial damage is a key determinant of recovery potential.26

Special Populations

Chagas cardiomyopathy, often associated with poor prognosis, may also present with RR. Data from a Brazilian cohort showed that improvement in LVEF to above 40% or an absolute increase of ≥10% from baseline was associated with a 55% reduction in mortality and need for heart transplantation over 15 years of follow-up.27

In patients with coronary artery disease and reduced LVEF undergoing high-risk percutaneous coronary intervention, approximately 51% had RR, with an average LVEF increase of 13.2% and improved composite clinical outcomes.28

Clinical Profile

Beyond aetiology, clinical variables influence recovery likelihood. Female sex and white race have been associated with greater likelihood of functional recovery and event-free survival, as demonstrated in multicentre studies involving patients with recent-onset cardiomyopathy.29 These findings underscore that both aetiology and clinical profile are key determinants in the course of RR in patients with HFrEF, with direct implications for risk stratification and individualised therapeutic decision-making.

Pathophysiological Mechanisms

LV RR is a dynamic and multifactorial process involving the interplay of structural, molecular, haemodynamic and neurohormonal mechanisms that lead to partial or complete restoration of cardiac structure and function. This phenomenon reflects the activation of intrinsic repair pathways and response to therapeutic interventions that promote myocardial recovery.

Cellular and Molecular Mechanisms

At the cellular level, RR is characterised by reduction in cardiomyocyte size, cytoskeletal reorganisation, restoration of mitochondrial function and attenuation of oxidative stress.30 The regression of pathological myocardial hypertrophy is closely linked to modulation of regulatory pathways, including changes in microRNA expression, imbalances in protein synthesis and degradation pathways, and alterations in cellular metabolism.31

Mitochondrial dysfunction, a hallmark of HF, improves markedly during RR, with restored oxidative phosphorylation, reduced reactive oxygen species and normalised mitochondrial calcium handling.32 This recovery of intracellular calcium dynamics re-establishes excitation–contraction coupling, essential for contractile function.33

Extracellular Matrix Remodelling

The dynamics of the extracellular matrix in RR is associated with reduced collagen deposition and, in some cases, regression of established fibrosis. This process includes a favourable balance between collagen synthesis and degradation. The regression of fibrosis is particularly important for the restoration of ventricular compliance and improvement in diastolic function.34

Neurohormonal Modulation

Therapies targeting the renin–angiotensin–aldosterone system (RAAS) and sympathetic nervous system are central to improving ventricular function. Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), aldosterone antagonists, β-blockers and angiotensin receptor–neprilysin inhibitors (ARNIs) attenuate hypertrophy, limit fibrosis and enhance performance.35,36 RAAS blockade reduces angiotensin II-mediated vasoconstriction, aldosterone-driven sodium retention, and direct profibrotic effects, while β-blockade mitigates sympathetic overstimulation, lowering heart rate, prolonging diastolic filling and decreasing oxygen demand.35,36 Natriuretic peptides (atrial natriuretic peptide [ANP], brain natriuretic peptide [BNP]) provide complementary antifibrotic and vasodilatory actions, alleviating volume and pressure overload and contributing to haemodynamic decompression.37

Haemodynamic Mechanisms

The occurrence of RR is closely linked to haemodynamic decompression, with reductions in ventricular pressure and volume overload. Left ventricular assist device (LVAD) implantation promotes RR by unloading the ventricle, decreasing wall stress and improving coronary perfusion, which favour normalisation of cell size and calcium handling.38 Myocardial revascularisation in ischaemic cardiomyopathy restores regional contractility and synchrony when viability is preserved, highlighting the concept of hibernating myocardium.39

In non-ischaemic cardiomyopathy, CRT enhances RR by improving contraction synchrony, reducing mitral regurgitation and relieving wall stress. In valvular disease, valve replacement leads to regression of hypertrophy and functional improvement, although irreversible fibrosis may limit complete reversibility.40

Metabolic Reprogramming

HF is associated with significant metabolic alterations, including a shift from fatty acid to glucose usage and impaired mitochondrial function. During RR there is often a restoration of normal metabolic flexibility, with improved fatty acid oxidation and enhanced mitochondrial biogenesis. This metabolic reprogramming is essential for sustained functional improvement.41

Inflammatory Resolution

Chronic inflammation plays a significant role in HF progression. RR is associated with resolution of inflammatory processes, including reduction in pro-inflammatory cytokines and increase in anti-inflammatory mediators. This shift in the inflammatory balance contributes to reduced myocardial injury and enhanced repair processes.42

Integration of Mechanisms

RR results from a spectrum of adaptive processes, ranging from immediate haemodynamic relief to sustained molecular reprogramming. The relative contribution of each mechanism varies depending on the underlying aetiology, duration of dysfunction, and therapeutic interventions used. Understanding these pathways not only helps identify patients likely to benefit from ventricular function recovery but also guides personalised therapies aimed at maximising functional improvement and minimising adverse outcomes (Figure 2).

Figure 2: Integrated Mechanisms of Cardiac Reverse Remodelling in Heart Failure

Article image
Download

Therapies Involved in Reverse Remodelling

β-Blockers, ACEIs, ARBs, ARNIs, mineralocorticoid receptor antagonists (MRAs) and sodium–glucose cotransporter 2 inhibitors (SGLT2Is) exert synergistic effects in reducing LV size and improving LVEF, in addition to their well-established benefits in reducing mortality and hospitalisations.43 However, each therapy contributes differently to the RR process.14

While the clinical benefit of neurohormonal therapies is indisputable, the isolated impact of ACEIs, ARBs, MRAs, ARNIs and SGLT2Is on RR remains controversial.44 In contrast, β-blockers consistently demonstrate favourable effects on LV geometry, including reductions in LV diameter and volume and improvements in LVEF. Subanalyses from CAPRICORN, MERIT-HF and CIBIS trials reported LVEF improvements ranging from 3.9% to 6% and consistent reductions in LV volumes.45–48 Mechanistic studies further suggest a more prominent remodelling effect with β-blockers than with ACEIs, with synergistic benefit when both are combined.49,50 A meta-analysis showed that carvedilol, bisoprolol and metoprolol succinate were superior to ACEIs, ARBs, ARNIs and MRAs in improving LVEF and reducing LV dimensions.44

Therapeutic response is amplified when these agents are used in combination and titrated to target doses. A prospective study of 598 patients with new-onset HFrEF (LVEF <35%) reported that 68% of patients achieved LVEF >35% after 6 months of optimal therapy and 77%, within 1 year. Notably, 89% of patients receiving all drugs at target doses improved to LVEF >35% at 6 months.51

Beyond pharmacological therapy, select patients benefit from device-based interventions. CRT improves contractility and reduces mitral regurgitation by correcting electrical dyssynchrony, leading to decreased LV end-diastolic volume (LVEDV), lower myocardial mass and increased LVEF. These effects are most pronounced in patients with left bundle branch block (LBBB), QRS >150 ms and non-ischaemic aetiology. In some, CRT normalises ventricular function (so-called ‘super responders’)particularly when LBBB is a causal factor in systolic dysfunction.52 Additionally, patients with significant right ventricular (RV) pacing (>20%) using single- or dual-chamber pacemakers benefit from CRT upgrade, which has been associated with reduced hospitalisation rates, significant reductions in LVEDV and improved LVEF.53

In advanced HF, long-term LVADs contribute to RR in select patients. Although registry data show recovery in only 1–2%, protocols combining LVAD support with intensive pharmacologic therapy have reported RR rates up to 40%.54,55 LVADs enhance cardiac output and blood pressure, facilitating optimisation of neurohormonal blockade.56 Furthermore, LV unloading leads to reduced LVEDV and left atrial volume, a more tubular ventricular shape, improved contractile efficiency, reduced hypertrophy and cytoskeletal injury and favourable changes in calcium-handling gene expression.56,57 However, these benefits are not observed in the right ventricle.

Clinical Implications

Patients with RR demonstrate more favourable outcomes compared with individuals with persistent HFrEF, particularly regarding mortality rates. However, HF-related events may still occur, and symptoms can persist.5 Patients who achieve RR with LVEF >50% present the lowest risk for HF-related death, all-cause mortality and HF rehospitalisation (Supplementary Figure 1).8

Predictors of RR

Several factors have been consistently associated with greater likelihood of LVEF improvement, including non-ischaemic aetiology, shorter HF duration, absence of late gadolinium enhancement on cardiac MRI, less severe initial remodelling and reduction in BNP levels following pharmacological treatment (Table 1).10,13

Table 1: Predictors of Reverse Remodelling: Occurrence, Maintenance and Risk of Relapse

Article image
Download

RR does not equate to definitive cure. Patients remain at risk for recurrent LVEF decline and HF relapse.58 Approximately 37% of patients who initially experience LVEF improvement later show deterioration.59 Factors associated with increased likelihood of relapse include advanced age, lower baseline LVEF and longer HF duration.21

Evidence suggests that isolated assessment of LVEF and symptoms is insufficient for comprehensive evaluation. In the TRED-HF study, patients who discontinued therapy had increases in blood pressure and heart rate, indicating enhanced neurohormonal activation. In patients who relapsed, LVEF decline preceded the rise in N-terminal proBNP (NT-proBNP), suggesting that NT-proBNP may not be sensitive for early relapse detection.58

Recent studies identified clinical predictors of long-term RR maintenance, including fewer symptoms, higher systolic blood pressure, absence of loop diuretics, greater LVEF improvement, larger septum and greater LV end-systolic diameter reduction.23

Management of Patients with Reverse Remodelling

In the setting of clinical, echocardiographic and biomarker improvement, the need to maintain indefinitely optimised HF therapy remains uncertain. Small human studies involving heterogeneous populations have yielded conflicting results.60,61 To address this question, the TRED-HF trial (2019) randomised 51 patients: 25 to a protocol of sequential withdrawal of spironolactone, β-blocker and ACEI or ARB, and 26 to continued guideline-directed medical therapy. The primary outcome was recurrence of LV dysfunction.11 In the withdrawal group, 11 patients (44%) had recurrence of ventricular dysfunction in the first 6 months, although there were no associated hospitalisations or death. In contrast, none of the 26 patients who maintained their therapy had recurrence. In a second phase of the trial, 25 of the 26 control group patients subsequently underwent treatment withdrawal; of these, nine (36%) had recurrent dysfunction within 6 months.11

These findings reinforce the concept that many patients are not cured of the underlying cardiomyopathy, but rather go into remission. At a 6-year follow-up, 65% of patients had had at least one recurrence of ventricular dysfunction.62 Higher baseline NT-proBNP level was associated with increased risk of relapse, and patients with recurrence had higher heart rates during follow-up, even when compared with patients off β-blockers who did not relapse. This suggests that heart rate may be a contributing mechanism to ventricular deterioration.63

Given that patients with RR often retain underlying molecular and biochemical alterations, it is plausible that ongoing pharmacological therapy is necessary to prevent recurrence. New studies are exploring partial medication withdrawal strategies. For instance, the CATHEDRAL-HF trial evaluated medication tapering while maintaining optimised carvedilol therapy in patients with HF with mildly reduced ejection fraction (HFmrEF). At 1-year follow-up the recurrence rates of ventricular dysfunction were similar between groups (14.8% in the withdrawal group versus 15.4% in controls; p=0.95), with no hospitalisation or death due to HF.64 That was a small, open-label pilot study, and larger trials with adequate non-inferiority power are needed to validate the findings.

Considering the central role of β-blockers in RR (through antiarrhythmic effects, heart rate control and neurohormonal blockade) maintenance of this class appears to be associated with improved outcomes in patients with HFmrEF.65 Other ongoing trials are assessing partial withdrawal of HF medications in HFrEF (Supplementary Table 2).

Few studies have investigated the withdrawal of HF medications in specific patient subgroups. The STOP-CRT trial evaluated different pharmacological strategies in 80 patients with HFmrEF after CRT implantation.66 In contrast to TRED-HF, this study found a similar 2-year increase in LVEDV of 7.5% across four groups: those who maintained full medical therapy; those who discontinued RAAS inhibitors; those who discontinued β-blockers; and those who discontinued both RAAS inhibitors and β-blockers. However, 21% of patients needed to restart the withdrawn medications due to comorbidities.

Another trial, WITHDRAW-HF, randomised 60 patients with tachycardia-induced cardiomyopathy who had undergone AF ablation and demonstrated RR. Patients were assigned to either medication withdrawal or continued guideline-directed therapy.67 At 6 months, 91.7% of patients in the withdrawal group maintained preserved ventricular function, and this percentage was 81.8% at 12 months, with no hospitalisations or adverse HF events reported (Table 2).

Table 2: Randomised Studies of Discontinuation or Reduction of Pharmacological Therapy in Patients with HFimpEF

Article image
Download

Other potentially ‘reversible’ aetiologies of HF, such as alcoholic cardiomyopathy, peripartum cardiomyopathy, prior myocarditis and chemotherapy-induced cardiotoxicity, still lack specific studies addressing pharmacologic management following recovery of ventricular function. These conditions may have a higher likelihood of sustained RR compared with genetic aetiologies. Ongoing randomised trials are exploring this topic (Supplementary Table 2). Given the distinct injurious and perpetuating mechanisms of myocardial damage, a deeper understanding of each underlying aetiology and the related markers associated with post-recovery remodelling deterioration is necessary.

Box 1: Independent Predictors of Sustained Reverse Remodelling in HFrEF

  • 2nd LVEF (%): OR 1.06 (per 1%)
  • 2nd LVESD (mm): OR 0.93 (per 1 mm)
  • 2nd IV septum (mm): OR 1.12 (per 1 mm)
  • Systolic BP (mmHg): OR 1.01 (per 1 mmHg)
  • NYHA class I–II: OR 1.86
  • No furosemide use: OR 1.87

BP = blood pressure; HFrEF = heart failure with reduced ejection fraction; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; NYHA = New York Heart Association.

Despite variations in study design and patient populations, one consistent finding across all trials is the proportion of patients who have recurrence of ventricular dysfunction, regardless of treatment arm. Observational studies suggest that up to one-fourth of patients with recovered ejection fraction may redevelop systolic dysfunction over time, independent of ongoing pharmacological therapy.4,60,68 Identifying this high-risk subgroup is essential for closer follow-up and caution when considering medication withdrawal (Box 1).23

In the light of current evidence, Brazilian, American and European guidelines recommend maintaining guideline-directed medical therapy for HFrEF even in patients with improved ventricular function, unless there is a compelling reason for discontinuation. If de-escalation is pursued, close clinical follow-up is imperative, including serial NT-proBNP measurements and echocardiographic assessments. Immediate reinstatement of therapy is advised at the first sign of functional decline (Supplementary Figure 2).15,17,43

Conclusion

RR should be considered a key therapeutic goal in HFrEF management, requiring systematic and individualised strategies. Early therapy optimisation with guideline-directed medical therapy is crucial for maximising RR. Patients with RR require ongoing clinical, echocardiographic and biomarker assessment. Full withdrawal of therapy should generally be avoided, particularly in idiopathic or ischaemic cardiomyopathies. For many patients, recovery represents therapy-dependent remission rather than cure, requiring vigilance and long-term individualised treatment strategies. The pursuit of RR should guide therapeutic decision-making at all stages of HF management.

Click here to view Supplementary Material.

References

  1. Kim GH, Uriel N, Burkhoff D. Reverse remodelling and myocardial recovery in heart failure. Nat Rev Cardiol 2018;15:83–96. 
    Crossref | PubMed
  2. Basuray A, French B, Ky B, et al. Heart failure with recovered ejection fraction. Circulation 2014;129:2380–7. 
    Crossref | PubMed
  3. Nadruz W, West E, Santos M, et al. Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail 2016;9:e002826. 
    Crossref | PubMed
  4. de Groote P, Fertin M, Duva Pentiah A, et al. Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after ß-blocker therapy. Circ Heart Fail 2014;7:434–9. 
    Crossref | PubMed
  5. Lupón J, Díez-López C, de Antonio M, et al. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail 2017;19:1615–23. 
    Crossref | PubMed
  6. Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart failure with recovered left ventricular ejection fraction: JACC scientific expert panel. J Am Coll Cardiol 2020;76:719–34. 
    Crossref | PubMed
  7. Merlo M, Pyxaras SA, Pinamonti B, et al. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 2011;57:1468–76. 
    Crossref | PubMed
  8. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol 2016;1:510–18. 
    Crossref | PubMed
  9. Florea VG, Rector TS, Anand IS, Cohn JN. Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the valsartan heart failure trial. Circ Heart Fail 2016;9:e003123. 
    Crossref | PubMed
  10. 1Gulati G, Udelson JE. Heart failure with improved ejection fraction: is it possible to escape one’s past? JACC Heart Fail 2018;6:725–33. 
    Crossref | PubMed
  11. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393:61–73. 
    Crossref | PubMed
  12. Lupón J, Gavidia-Bovadilla G, Ferrer E, et al. Dynamic trajectories of left ventricular ejection fraction in heart failure. J Am Coll Cardiol 2018;72:591–601. 
    Crossref | PubMed
  13. Aimo A, Gaggin HK, Barison A, et al. Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction. JACC Heart Fail 2019;7:782–94. 
    Crossref | PubMed
  14. Saraon T, Katz SD. Reverse remodeling in systolic heart failure. Cardiol Rev 2015;23:173–81. 
    Crossref | PubMed
  15. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895–1032. 
    Crossref | PubMed
  16. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:4901. 
    Crossref | PubMed
  17. Marcondes-Braga FG, Moura LAZ, Issa VS, et al. Emerging topics update of the Brazilian heart failure guideline – 2021. Arq Bras Cardiol 2021;116:1174–212. 
    Crossref | PubMed
  18. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, heart failure association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail 2021;27:387–413. 
    Crossref | PubMed
  19. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021;23:352–80. 
    Crossref | PubMed
  20. Halliday BP, Cleland JGF. Maintaining success for patients with dilated cardiomyopathy and remission of heart failure. JACC Basic Transl Sci 2022;7:500–3. 
    Crossref | PubMed
  21. Kasiakogias A, Ragavan A, Halliday BP. Your heart function has normalized: what next after TRED-HF? Curr Heart Fail Rep 2023;20:542–54. 
    Crossref | PubMed
  22. Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol 2012;60:2465–72. 
    Crossref | PubMed
  23. Furquim SR, Bocchi EA, Lira MTSS, et al. Predictors of sustained reverse remodelling in patients with heart failure with reduced ejection fraction. ESC Heart Fail 2025;12:2190–9. 
    Crossref | PubMed
  24. Hellawell JL, Margulies KB. Myocardial reverse remodeling. Cardiovasc Ther 2012;30:172–81. 
    Crossref | PubMed
  25. Amorim S, Rodrigues J, Campelo M, et al. Left ventricular reverse remodeling in dilated cardiomyopathy: maintained subclinical myocardial systolic and diastolic dysfunction. Int J Cardiovasc Imaging 2017;33:605–13. 
    Crossref | PubMed
  26. Izumi C, Kitai T, Kume T, et al. Effect of left ventricular reverse remodeling on long-term outcomes after aortic valve replacement. Am J Cardiol 2019;124:105–12. 
    Crossref | PubMed
  27. Lira MTSS, Furquim SR, Marchi DC, et al. Left ventricular reverse remodeling: a predictor of survival in chagasic cardiomyopathy patients with a reduced ejection fraction. PLOS Negl Trop Dis 2025;19:e0013053. 
    Crossref | PubMed
  28. Daubert MA, Massaro J, Liao L, et al. High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction. Am Heart J 2015;170:550–8. 
    Crossref | PubMed
  29. McNamara DM, Starling RC, Cooper LT, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol 2011;58:1112–18. 
    Crossref | PubMed
  30. Koitabashi N, Kass DA. Reverse remodeling in heart failure: mechanisms and therapeutic opportunities. Nat Rev Cardiol 2011;9:147–57. 
    Crossref | PubMed
  31. Martin TG, Juarros MA, Leinwand LA. Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nat Rev Cardiol 2023;20:347–63. 
    Crossref | PubMed
  32. Miranda-Silva D, Rodrigues PG, Alves E, et al. Mitochondrial reversible changes determine diastolic function adaptations during myocardial (reverse) remodeling. Circ Heart Fail 2020;13:e006170. 
    Crossref | PubMed
  33. Gorski PA, Ceholski DK, Hajjar RJ. Altered myocardial calcium cycling and energetics in heart failure: a rational approach for disease treatment. Cell Metab 2015;21:183–94. 
    Crossref | PubMed
  34. Birks EJ. Molecular changes after left ventricular assist device support for heart failure. Circ Res 2013;113:777–91. 
    Crossref | PubMed
  35. Falcão-Pires I, Ferreira AF, Trinidade F, et al. Mechanisms of myocardial reverse remodelling and its clinical significance: a scientific statement of the ESC Working Group on Myocardial Function. Eur J Heart Fail 2024;26:1454–79. 
    Crossref | PubMed
  36. Cheema Y, Zhao W, Zhao T, et al. Reverse remodeling and recovery from cachexia in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2012;303:H486–95. 
    Crossref | PubMed
  37. Jaiswal A, Nguyen VQ, Carry BJ, le Jemtel TH. Pharmacologic and endovascular reversal of left ventricular remodeling. J Card Fail 2016;22:829–39. 
    Crossref | PubMed
  38. Burkhoff D, Topkara VK, Sayer G, Uriel N. Reverse remodeling with left ventricular assist devices. Circ Res 2021;128:1594–612. 
    Crossref | PubMed
  39. Castelvecchio S, Frigelli M, Sturla F, et al. Elucidating the mechanisms underlying left ventricular function recovery in patients with ischemic heart failure undergoing surgical remodeling: a 3-dimensional ultrasound analysis. J Thorac Cardiovasc Surg 2023;165:1418–29. 
    Crossref | PubMed
  40. Treibel TA, Kozor R, Schofield R, et al. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol 2018;71:860–71. 
    Crossref | PubMed
  41. Green PG, Watson WD, Bussmann BM, et al. Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J 2025;46:2422–33. 
    Crossref | PubMed
  42. Bilchick K, Kothari H, Narayan A, et al. Cardiac resynchronization therapy reduces expression of inflammation-promoting genes related to interleukin-1ß in heart failure. Cardiovasc Res 2020;116:1311–22. 
    Crossref | PubMed
  43. van der Meer P, Gaggin HK, Dec GW. ACC/AHA versus ESC guidelines on heart failure: JACC guideline comparison. J Am Coll Cardiol 2019;73:2756–68. 
    Crossref | PubMed
  44. Kramer DG, Trikalinos TA, Kent DM, et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010;56:392–406. 
    Crossref | PubMed
  45. Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004;109:201–6. 
    Crossref | PubMed
  46. Palazzuoli A, Bruni F, Puccetti L, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002;4:765–70. 
    Crossref | PubMed
  47. Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the cardiac insufficiency bisoprolol study (CIBIS). Circulation 1997;96:2197–205. 
    Crossref | PubMed
  48. Groenning BA, Nilsson JC, Sondergaard L, et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072–80. 
    Crossref | PubMed
  49. Khattar RS, Senior R, Soman P, et al. Regression of left ventricular remodeling in chronic heart failure: comparative and combined effects of captopril and carvedilol. Am Heart J 2001;142:704–13. 
    Crossref | PubMed
  50. Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The Carvedilol and ACE-inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN). Cardiovasc Drugs Ther 2004;18:57–66. 
    Crossref | PubMed
  51. Veltmann C, Duncker D, Doering M, et al. Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study. Eur Heart J 2024;45:2771–81. 
    Crossref | PubMed
  52. Castellant P, Fatemi M, Orhan E, et al. Patients with non-ischaemic dilated cardiomyopathy and hyper-responders to cardiac resynchronization therapy: characteristics and long-term evolution. Europace 2009;11:350–5. 
    Crossref | PubMed
  53. Merkely B, Hatala R, Wranicz JK, et al. Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial. Eur Heart J 2023;44:4259–69. 
    Crossref | PubMed
  54. Pan S, Aksut B, Wever-Pinzon OE, et al. Incidence and predictors of myocardial recovery on long-term left ventricular assist device support: results from the United Network for Organ Sharing database. J Heart Lung Transplant 2015;34:1624–9. 
    Crossref | PubMed
  55. Birks EJ, Drakos SG, Patel SR, et al. Prospective multicenter study of myocardial recovery using left ventricular assist devices (RESTAGE-HF [Remission from Stage D Heart Failure]): medium-term and primary end point results. Circulation 2020;142:2016–28. 
    Crossref | PubMed
  56. Pamias-Lopez B, Ibrahim ME, Pitoulis FG. Cardiac mechanics and reverse remodelling under mechanical support from left ventricular assist devices. Front Cardiovasc Med 2023;10:1212875. 
    Crossref | PubMed
  57. McCarthy PM, Nakatani S, Vargo R, et al. Structural and left ventricular histologic changes after implantable LVAD insertion. Ann Thorac Surg 1995;59:609–13. 
    Crossref | PubMed
  58. Halliday BP, Owen R, Gregson J, et al. Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF. Eur J Heart Fail 2021;23:293–301. 
    Crossref | PubMed
  59. Merlo M, Stolfo D, Anzini M, et al. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist? J Am Heart Assoc 2015;4:e001504. 
    Crossref | PubMed
  60. Moon J, Ko Y-G, Chung N, et al. Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 2009;25:e147–50. 
    Crossref | PubMed
  61. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006;152:509–13. 
    Crossref | PubMed
  62. Cheng L, Hammersley D, Ragavan A, et al. Long-term follow-up of the TRED-HF trial: implications for therapy in patients with dilated cardiomyopathy and heart failure remission. Eur J Heart Fail 2025;27:113–23. 
    Crossref | PubMed
  63. Halliday BP, Vazir A, Owen R, et al. Heart rate as a marker of relapse during withdrawal of therapy in recovered dilated cardiomyopathy. JACC Heart Fail 2021;9:509–17. 
    Crossref | PubMed
  64. Belfort SPB, Bocchi EA, Cafezeiro CRF, et al. Carvedilol as single therapy for heart failure with improved ejection fraction: a randomized clinical trial (CATHEDRAL-HF). JACC Heart Fail 2025;13:1041–44. 
    Crossref | PubMed
  65. Enzan N, Matsushima S, Ide T, et al. Beta-blocker use is associated with prevention of left ventricular remodeling in recovered dilated cardiomyopathy. J Am Heart Assoc 2021;10:e019240. 
    Crossref | PubMed
  66. Nijst P, Martens P, Dauw J, et al. Withdrawal of neurohumoral blockade after cardiac resynchronization therapy. J Am Coll Cardiol 2020;75:1426–38. 
    Crossref | PubMed
  67. Segan L, Kistler PM, Nanayakkara S, et al. Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial. Eur Heart J 2025:ehaf563; epub ahead of press. 
    Crossref | PubMed
  68. Park CS, Park JJ, Mebazaa A, et al. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. J Am Heart Assoc 2019;8:e011077. 
    Crossref | PubMed
Previous Volume Article Next Volume Article